Sorafenib for 9,923 Patients with Hepatocellular Carcinoma: An Analysis from National Health Insurance Claim Data in South Korea
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in South Korea. Methods: This population-based retrospective, single-arm, observational study used the Korean National Health Insurance database to identify patients with HCC who received sorafenib between July 1, 2008, and December 31, 2014. A total of 9,923 patients were recruited in this study. Results: Among 9,923 patients, 6,669 patients (68.2%) received loco-regional therapy prior to sorafenib, and 1,565 patients (15.8%) received combination therapy with concomitant sorafenib; 2,591 patients (26.1%) received rescue therapy after sorafenib, and transarterial chemoembolization was the most common modality applied in 1,498 patients (15.1%). A total of 3,591 patients underwent rescue therapy after sorafenib, and the median overall survival was 14.5 months compared to 4.6 months in 7,332 patients who received supportive care after sorafenib. The mean duration of sorafenib administration in all patients was 105.7 days; 7,023 patients (70.8%) received an initial dose of 600 to 800 mg. The longest survival was shown in patients who received the recommended dose of 800 mg, subsequently reduced to 400 mg (15.0 months). The second longest survival was demonstrated in patients with a starting dose of 800 mg, followed by a dose reduction to 400–600 mg (9.6 months). Conclusions: Real-life data show that the efficacy of sorafenib seems similar to that observed in clinical trials, suggesting that appropriate subsequent therapy after sorafenib might prolong patient survival.
Abstract
Background/Aims: Sorafenib is the standard of care in the management of advanced hepatocellular carcinoma (HCC). The purpose of this study was to investigate the characteristics, treatment patterns and outcomes of sorafenib among HCC patients in South Korea. Methods: This population-based retrospective, single-arm, observational study used the Korean National Health Insurance database to identify patients with HCC who received sorafenib between July 1, 2008, and December 31, 2014. A total of 9,923 patients were recruited in this study. Results: Among 9,923 patients, 6,669 patients (68.2%) received loco-regional therapy prior to sorafenib, and 1,565 patients (15.8%) received combination therapy with concomitant sorafenib; 2,591 patients (26.1%) received rescue therapy after sorafenib, and transarterial chemoembolization was the most common modality applied in 1,498 patients (15.1%). A total of 3,591 patients underwent rescue therapy after sorafenib, and the median overall survival was 14.5 months compared to 4.6 months in 7,332 patients who received supportive care after sorafenib. The mean duration of sorafenib administration in all patients was 105.7 days; 7,023 patients (70.8%) received an initial dose of 600 to 800 mg. The longest survival was shown in patients who received the recommended dose of 800 mg, subsequently reduced to 400 mg (15.0 months). The second longest survival was demonstrated in patients with a starting dose of 800 mg, followed by a dose reduction to 400–600 mg (9.6 months). Conclusions: Real-life data show that the efficacy of sorafenib seems similar to that observed in clinical trials, suggesting that appropriate subsequent therapy after sorafenib might prolong patient survival.
참고문헌 (29)
- Torre LA, "Global cancer statistics, 2012", CA Cancer J Clin, 65, pp.87~108 (2015)
- Yang WJ, "The impact of socioeconomic status on mortality in patients with hepatocellular carcinoma : a Korean national cohort study", Gut Liver, 16, pp.976~984 (2022)
- Bruix J, "Management of hepatocellular carcinoma : an update", Hepatology, 53, pp.1020~1022 (2011)
- Lee HA, "Change in the recurrence pattern and predictors over time after complete cure of hepatocellular carcinoma", Gut Liver, 15, pp.420~429 (2021)
- Korean Liver Cancer Association(KLCA)and National Cancer Center(NCC)Korea, "2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma", Clin Mol Hepatol, 28, pp.583~705 (2022)
- Torimura T, "Optimizing the management of intermediate-stage hepatocellular carcinoma : current trends and prospects", Clin Mol Hepatol, 27, pp.236~245 (2021)
- Rajendran L, "The management of post-transplantation recurrence of hepatocellular carcinoma", Clin Mol Hepatol, 28, pp.1~16 (2022)
- Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359, pp.378~390 (2008)
- Cheng AL, "Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial", Lancet Oncol, 10, pp.25~34 (2009)
- Kim DY, "Real-life experience of sorafenib treatment for hepatocellular carcinoma in Korea : from GIDEON data", Cancer Res Treat, 48, pp.1243~1252 (2016)
- Marrero JA, "Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups : the GIDEON study", J Hepatol, 65, pp.1140~1147 (2016)
- Geschwind JF, "TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice : final analysis of GIDEON", Radiology, 279, pp.630~640 (2016)
- Ahn YE, "Comparison of sorafenib versus hepatic arterial infusion chemotherapy-based treatment for advanced hepatocellular carcinoma with portal vein tumor thrombosis", Gut Liver, 15, pp.284~294 (2021)
- Kudo M, "Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial", Lancet, 391, pp.1163~1173 (2018)
- Bruix J, "Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE) : a randomised, double-blind, placebocontrolled, phase 3 trial", Lancet, 389, pp.56~66 (2017)
- El-Khoueiry AB, "Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate 040) : an open-label, non-comparative, phase 1", 2 dose escalation and expansion trial, 2017, pp.389, 2492~2502
- Abou-Alfa GK, "Cabozantinib in patients with advanced and progressing hepatocellular carcinoma", N Engl J Med, 379, pp.54~63 (2018)
- Finn RS, "Pembrolizumab as secondline therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial", J Clin Oncol, 38, pp.193~202 (2020)
- Zhu AX, "Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH) : a randomised, double-blind, multicentre, phase 3 trial", Lancet Oncol, 16, pp.859~870 (2015)
- Lencioni R, "GIDEON(Global Investigation of therapeutic Decisions in hepatocellular carcinoma and of its treatment with sorafeNib) : second interim analysis", Int J Clin Pract, 68, pp.609~617 (2014)
- Park JW, "Global patterns of hepatocellular carcinoma management from diagnosis to death : the BRIDGE study", Liver Int, 35, pp.2155~2166 (2015)
- Iavarone M, "Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib", Hepatology, 62, pp.784~791 (2015)
- Finn RS, "Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC : additional analyses from the phase III RESORCE trial", J Hepatol, 69, pp.353~358 (2018)
- Yoo C, "Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma", Invest New Drugs, 37, pp.567~572 (2019)
- Reiss KA, "Starting dose of sorafenib for the treatment of hepatocellular carcinoma : a retrospective, multi-institutional study", J Clin Oncol, 35, pp.3575~3581 (2017)
- Daniele B, "Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study", Future Oncol, 11, pp.2553~2562 (2015)
- Rimola J, "Complete response under sorafenib in patients with hepatocellular carcinoma : relationship with dermatologic adverse events", Hepatology, 67, pp.612~622 (2018)
- Reig M, "Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib", J Hepatol, 61, pp.318~324 (2014)
- Ponziani FR, "Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma", Liver Int, 36, pp.1033~1042 (2016)